Delivery Order SPE2DB22D3016-SPE2DB25FBBT9
- Not listed
- The Defense Logistics Agency awarded a $48,077.16 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Ocrevus 300 mg/10 ml vials. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a $24,038.58 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on September 8, 2025, with an ultimate completion date of September 29, 2025. This non-set-aside competitive award represents a single delivery order issued against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's facility in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ocrevus 300 mg/10 mL vials valued at $48,077.16. This is a firm fixed-price delivery order with an ultimate completion date of October 9, 2025, and represents a non-competitive award under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $120,192.80 and firm fixed pricing. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This is an unrestricted, competitively awarded delivery order with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ocrevus 300 mg/10 mL vials, valued at $96,154.24 with a firm fixed price structure. The award is non-competitive with no set-aside designation and is scheduled for completion by October 2, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which...
- The Defense Logistics Agency awarded a $48,077.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on September 19, 2025, with an ultimate completion date of October 10, 2025. This non-competitive delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $12,019.28 delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 12, 2025, and performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $36,057.84 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This firm fixed-price, non-set-aside contract is scheduled for completion by August 8, 2025, with performance at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen, a major pharmaceutical distributor and critical vendor for federal medical procurement, will fulfill this order as part of its ongoing...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ocrevus 300 mg/10 ml vials. The contract, valued at $120,192.80 with a firm fixed price structure, represents a competitively awarded, non-set-aside delivery order with an ultimate completion date of October 8, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed price delivery order with an ultimate completion date of June 24, 2025, and represents a non-competitive, non-set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBBT9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $85,193.27. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is scheduled for completion by August 4, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion comprehensive global pharmaceutical support vehicle running through December 2026. AmerisourceBergen serves as a critical prime vendor for the Defense Logistics Agency's Medical Supply Chain, delivering a broad range of pharmaceuticals, biologics, and medical supplies to support military healthcare programs worldwide. The company's status as a major pharmaceutical distributor and established federal contractor demonstrates its capability to fulfill specialized medical procurement requirements for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $85.2k | 7/14/25 |